Orchid Cellmark to Announce Fourth Quarter and Full Year 2007 Financial Results on March 6, 2008

PRINCETON, N.J., Feb. 29 Orchid Cellmark Inc.(Nasdaq: ORCH), a leading worldwide provider of identity DNA testing services,will release its fourth quarter and full year 2007 financial results onThursday, March 6, 2008 at approximately 7:00 am EST, and is hosting aconference call and webcast to discuss the results at 10:00 a.m. EST on thesame day. Management will discuss financial results for the fourth quarterand full year 2007 as well as operating highlights. A question-and-answersession will follow management's discussion. All interested parties areencouraged to listen to the live conference call or the live or archivedwebcast.

About Orchid Cellmark

Orchid Cellmark is a leading provider of identity DNA testing services forthe human identity and agriculture markets. In the human identity area, thecompany provides DNA testing services for forensic, family relationship andsecurity applications. In the agriculture field, Orchid Cellmark provides DNAtesting services for selective trait breeding. Orchid Cellmark's strongmarket positions in these segments reflect the company's accreditedlaboratories in the U.S. and U.K., its innovative genetic analysistechnologies and expertise, and the world-renowned Cellmark brand that hasbeen associated with exceptional quality, reliability and customer service fornearly two decades. More information on Orchid Cellmark can be found athttp://www.orchid.com.Conference Call Details Date and Time: Thursday, March 6, 2008 at 10:00am EST Dial-In: US/Canada: (877) 266-0703 Int'l/Local: (706) 643-7682 Conference ID: 37503567 Webcast: Live webcast and replay available via the Investor Relations section of the company's website at http://www.orchid.com. The webcast will be available for 90 days.

SOURCE Orchid Cellmark Inc.

Latest Press Release on General News

Precision oncology company Flindr Therapeutics announces €20 million Series A financing to advance first-in-class small molecule inhibitors

V-Bio Ventures leads international syndicate which includes Johnson & Johnson Innovation – JJDC, Inc., QBIC Fund, Flanders Future Tech Fund, Curie Capital as well as seed investor...

Rett Syndrome Research Trust Partners with Vivalink to Shift Symptom Assessment Paradigms in Rett Syndrome

Vivalink's remote patient monitoring solutions accelerate research into rare neurological disorder CAMPBELL, Calif. , April 23, 2024 /PRNewswire/ -- Vivalink , a leading pro...

World IBS Day - April 19th: Raising Awareness for Everyone with IBS

Debunking myths about Irritable Bowel Syndrome TORONTO , April 18, 2024 /PRNewswire/ -- IBS is a chronic gastrointestinal disorder with symptoms like abdominal pain, bloating,...

Important step taken on the Canada Disability Benefit in Budget 2024, but funding falls short

More work must be done to lift Canadians with disabilities out of poverty TORONTO , April 17, 2024 /CNW/ - The federal government has taken an important step on the Canada Di...

Hydrinity Accelerated Skin Science Introduces MicroFusion Technology and Expands Facial Skincare Line with PRELUDE Facial Treatment Cleanser and HYDRI-C Vitamin C Moisturizer

The Next Generation Technology with the Power to Transform Skin MONROE, La. , April 15, 2024 /PRNewswire/ -- Hydrinity Accelerated Skin Science announced today the launch of t...